In this study we provide evidence that anti-angiogenic therapy by targeting the VEGF signaling axis can counteract tumor endothelial cell anergy in renal cell carcinoma (RCC). This evidence concerns the gene VEGFA and hereditary clear cell renal cell carcinoma.